Biovica: Significant growth at less significant absolut levels - Redeye

Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have increased by >300% in 2023/23. The total sales of SEK 7.4m is still below the SEK 10m target. IVD sales are still modest in absolute levels at SEK 0.42m. Biovica has also secured two Master Service agreements, adding SEK 1.2m plus SEK 1.7m in initial order value.

Länk till analysen i sin helhet: https://www.redeye.se/research/1016232/biovica-significant-growth-at-less-significant-absolut-levels?utm_source=finwire&utm_medium=RSS